Similar articles

• The effect of renal failure and hyperkalemia on the duration of pancuronium neuromuscular blockade in man.

  Miller RD, Stevens WC, Way WL. Miller RD, et al. Anesth Analg. 1973 Jul-Aug;52(4):661-6. Anesth Analg. 1973. PMID: 4352150 No abstract available.
• Pancuronium bromide: experiences in 100 pediatric patients.

  Bennett EJ, Daughety MJ, Bowyer DE, Stephen CR. Bennett EJ, et al. Anesth Analg. 1971 Sep-Oct;50(5):798-807. Anesth Analg. 1971. PMID: 4107121 No abstract available.
• Clinical study of pancuronium bromide as a neuromuscular blocking agent in anaesthesia.

  Telivuo L, Ertama P, Aalto-Setälä M, Appelqvist R, Kaljunen A, Karhunen U, Nuuttila K, Welling I. Telivuo L, et al. Acta Anaesthesiol Scand. 1971 Dec;15(4):261-6. doi: 10.1111/j.1399-6576.1971.tb00770.x. Acta Anaesthesiol Scand. 1971. PMID: 4345074 No abstract available.
• Pancuronium bromide: a review of its pharmacological properties and clinical application.

  Speight TM, Avery GS. Speight TM, et al. Drugs. 1972;4(3):163-226. doi: 10.2165/00003495-197204030-00002. Drugs. 1972. PMID: 4264763 Review. No abstract available.
• [Pharmacodynamics of new volatile anesthetics and the keypoints of its application].

  Kosaka F. Kosaka F. Geka Chiryo. 1969 May;20(5):513-22. Geka Chiryo. 1969. PMID: 4897040 Review. Japanese. No abstract available.